Skip to main content

Market Overview

AbbVie Falling After Q4 Report, 2016 Guidance Affirmation


Shares of AbbVie Inc (NYSE: ABBV) were trading lower by more than 4 percent early Friday morning after the company reported its fourth quarter results.

AbbVie earned $1.13 per share in the fourth quarter on revenue of $6.36 billion. Wall Street analysts were expecting the company to earn $1.12 per share on revenue of $6.39 billion.

Humira global sales rose 16.0 percent from a year ago to $3.717 billion and was driven by "exceptional" growth of 20.7 percent in the US where sales totaled $2.332 billion.

AbbVie added its sales growth of 18.4 percent from a year ago was also driven by $554 million in global VIEKIRA sales and Global IMBRUVICA sales which totaled $343 million. The company also noted "strong operational growth" from sales of Duodopa, Creon and Lupron.

"AbbVie delivered strong performance in 2015, exceeding original sales, margin expansion, and earnings projections for the year," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We achieved significant growth in 2015, and expect to continue building on that momentum in 2016 with another year of strong performance."

Looking forward to the full year fiscal 2016, AbbVie reaffirmed its earnings per share guidance of $4.90 to $5.10 which represents "strong" double-digit growth. Wall Street analysts were already estimating the company to earn $5.03 per share.


Related Articles (ABBV)

View Comments and Join the Discussion!

Posted-In: AbbVie Biopharamceutical Biopharmaceutical Stocks HumiraEarnings News Guidance Movers

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at